Dr. Javier J. Zulueta enters boardroom as Chief Medical Officer, Pulmonology, with potential of changing the lung cancer survival curve in a single generation
NEW YORK–(BUSINESS WIRE)–Qure.ai has appointed Dr. Javier J. Zulueta, previously Professor of Medicine at the Icahn School of Medicine at Mount Sinai in New York and Pulmonary Division Chief at Mount Sinai Morningside Hospital, to a new position of Chief Medical Officer, Pulmonology.
The role will dovetail his deep clinical insight to the ongoing research & development in lung health AI and digital health care coordination solutions to bolster Qure.ai’s pace of business expansion in the USA and Europe.
Prashant Warier, Founder and CEO of Qure.ai states, “We warmly welcome Dr. J, Zulueta to bring his unmatched global expertise in lung cancer screening and management to Qure.ai. His knowledge will be instrumental in the ongoing strategic development of our Lung Cancer Suite of AI-powered solutions and to drive clinical deployments in health systems and hospitals at scale.”
Dr. Javier J. Zulueta, Chief Medical Officer at Qure.ai states, “Lung cancer remains the deadliest cancer in the world, not because we can’t treat it, but because we find it too late. We stand at a pivotal moment in clinical and technology disruption where the power of AI can be harnessed safely to turn small incidental lung nodule findings into lifesaving interventions. Joining Qure.ai puts me at the epicentre of this change – we have the potential to change the survival curve in a single generation.”
Dr. Zulueta brings more than three decades of experience as a physician, scientist, academician and pioneer in interventional pulmonology, lung cancer screening and pulmonary nodule/disease management. Prior to Mount Sinai, he founded and led the inaugural Department of Respiratory Medicine at Clinica Universidad de Navarra in Pamplona, Spain’s premier medical school, where he launched the country’s first lung cancer screening program as Principal Investigator of the International Early Lung Cancer Action Program (IELCAP). His passion in the advancement of early lung cancer detection through medical technology has also led to him taking a number of past roles with commercial companies as an Advisory Board Member.
The new CMO appointment builds on a rapid pace of business scaling for Qure.ai in the USA. At the start of 2025 it appointed Jim Mercadante as Chief Commercial Officer, followed by a dozen business development, sales and strategic account management appointments across the States. Recently, Qure.ai was also recognized as a TIME100 Most Influential Company 2025 for the use of AI to reshape access and diagnosis of high-burden diseases worldwide. Qure.ai is deployed in more than 100 countries and has 18 FDA cleared findings.
Qure.ai is a global health tech company that innovates AI-enabled healthcare solutions to drive early clinical diagnosis and boost seamless patient care coordination. Qure’s solutions power the efficient identification and management of Tuberculosis (TB), Lung Cancer and Neurocritical findings to support clinicians and propel developments in the pharmaceutical and medical device industries. The company empowers healthcare workers or health systems by helping to identify conditions fast, prioritize treatment planning and ultimately improve quality of patient life.
Qure.ai has deployments in over 100 countries, with regional offices in New York, London, Dubai and Mumbai. It is a TIME100 Most Influential Company 2025.
Contacts
For media queries:
Amrutha Joseph – Amrutha.joseph@qure.ai / Georgina Wright – Georgina.wright@qure.ai
